Lexicon Pharmaceuticals, Inc. (LXRX)
2.245
+0.06
(+2.51%)
USD |
NASDAQ |
Sep 02, 16:00
2.245
0.00 (0.00%)
After-Hours: 20:00
Lexicon Pharmaceuticals Research and Development Expense (TTM) : 59.79M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 59.79M |
| March 31, 2026 | 58.02M |
| December 31, 2025 | 60.50M |
| September 30, 2025 | 74.76M |
| June 30, 2025 | 81.81M |
| March 31, 2025 | 83.74M |
| December 31, 2024 | 82.85M |
| September 30, 2024 | 72.00M |
| June 30, 2024 | 63.75M |
| March 31, 2024 | 60.65M |
| December 31, 2023 | 58.33M |
| September 30, 2023 | 57.59M |
| June 30, 2023 | 50.63M |
| March 31, 2023 | 49.49M |
| December 31, 2022 | 52.39M |
| September 30, 2022 | 54.90M |
| June 30, 2022 | 60.03M |
| March 31, 2022 | 57.00M |
| December 31, 2021 | 54.75M |
| September 30, 2021 | 39.02M |
| June 30, 2021 | 60.60M |
| March 31, 2021 | 107.28M |
| December 31, 2020 | 149.39M |
| September 30, 2020 | 188.91M |
| June 30, 2020 | 177.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 133.63M |
| December 31, 2019 | 90.98M |
| September 30, 2019 | 63.12M |
| June 30, 2019 | 50.21M |
| March 31, 2019 | 64.05M |
| December 31, 2018 | 99.72M |
| September 30, 2018 | 134.58M |
| June 30, 2018 | 160.47M |
| March 31, 2018 | 160.93M |
| December 31, 2017 | 156.81M |
| September 30, 2017 | 150.05M |
| June 30, 2017 | 163.45M |
| March 31, 2017 | 184.73M |
| December 31, 2016 | 178.15M |
| September 30, 2016 | 168.19M |
| June 30, 2016 | 138.77M |
| March 31, 2016 | 111.32M |
| December 31, 2015 | 95.19M |
| September 30, 2015 | 84.78M |
| June 30, 2015 | 85.67M |
| March 31, 2015 | 84.89M |
| December 31, 2014 | 84.38M |
| September 30, 2014 | 84.61M |
| June 30, 2014 | 86.00M |
| March 31, 2014 | 89.71M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Viatris, Inc. | 995.00M |
| Pfizer Inc. | 10.82B |
| ANI Pharmaceuticals, Inc. | 49.91M |
| Corcept Therapeutics, Inc. | 253.86M |
| Veru, Inc. | 11.76M |